The development of the anti-tumor necrosis factor α (TNF-α) antibody infliximab defines a ground-breaking moment in the treatment of inflammatory bowel diseases (IBDs), namely Crohn’s disease (CD) and ulcerative colitis (UC). The gene discussed is TNF; the disease is ulcerative colitis.